细胞色素氧化酶CYP2C9的研究进展

被引:18
作者
卢爱华
舒焱
周宏灏
机构
[1] 深圳康力医药公司!广东深圳
[2] School of Pharmac!University of CaliforniaBox Department of Biopharmaceutics Parnassus AvenuSan FranciscoCA - USA
[3] 湖南医科大学基础与临床药理研究所!长沙
基金
国家自然科学基金重点项目;
关键词
CYP2C9; 药物代谢; 遗传多态性; 基因突变; 遗传药理学;
D O I
10.13699/j.cnki.1001-6821.2000.05.017
中图分类号
R329.2 [人体细胞学];
学科分类号
摘要
CYP2C9是人类肝脏中含量丰富的一种CYP450酶,它能代谢和/或活化许多种药物、前致癌物、前毒物和致突变剂。CYP2C9基因具有遗传多态性,在人类存在几种等位基因的突变体。本文从基因结构、底物和探针药、影响其活性的因素、遗传多态性的分子机制等方面综述CYP2C9的研究进展。
引用
收藏
页码:381 / 385
页数:5
相关论文
共 22 条
[1]  
Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Kimura M,Ieiri I,Mamiya K,et al. Therapeutic Drug Monitoring . 1998
[2]  
Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Furuya H,Fernandez-Salguero P,Gregory W,et al. Pharmacogenetics . 1995
[3]  
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Aithal GP,Day CP,Kesteven PJ,et al. The Lancet . 1999
[4]  
Correlation of human P4502C substrate specificities with primary structure-warfarin as a probe. Kaminsky. LS,de Morais SMF,Faletto MB,et al. Molecular Pharmacology . 1993
[5]  
cDNA and amino acid sequences of two members of the human P450IIC gene subfamily. Kimura S,Pastewka J,Gelboin HV,et al. Nucleic Acids Research . 1987
[6]  
Human hepatic cytochrome P450 catalyzes the rate limiting pathway of torasemide metabolism. Miners JO,Rees DLP,Valenre L,et al. Journal of Pharmacology and Experimental Therapeutics . 1995
[7]  
The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Sullivan-Klose TH,Ghanayem BI,Bell DA,et al. Pharmacogenetics . 1996
[8]  
Inheritance of poor phenytoin parahydroxylation capacity in an Dutch family. Vermeij P,Ferrari MD,Buruma OJ,et al. Clinical Pharmacology and Therapeutics . 1988
[9]  
Phenytoin: pharmacogenetic polymorphism of 4 -hydroxylation. Inaba T. Pharmacology and Therapeutics . 1990
[10]  
Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4’-hydroxylation activities in livers of Japanese and Caucasian Populations. Inoue K,Yamazaki H,Imiya K,et al. Pharmacogenetics . 1997